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Dysregulation of apoptosis plays an important role in tumour progression and resistance to chemotherapy. The X-linked inhibitor of
apoptosis (XIAP) is considered to be the most potent caspase inhibitor of all known inhibitor of apoptosis-family members. Only
recently, an antagonist of XIAP has been identified, termed Smac/DIABLO. To explore the relevance of antiapoptotic XIAP and
proapoptotic Smac/DIABLO for tumour progression in renal cell carcinomas (RCCs), we analysed XIAP and Smac/DIABLO mRNA
and protein expression in the primary tumour tissue from 66 RCCs of all major histological types by quantitative real-time PCR,
Western blot and ELISA. X-linked inhibitor of apoptosis and Smac/DIABLO mRNA expression was found in all RCCs. Importantly,
the relative XIAP mRNA expression levels significantly increased from early (pT1) to advanced (pT3) tumour stages (P¼0.0002) and
also with tumour dedifferentiation (P¼0.04). Western blot analysis confirmed the tumour stage-dependent increase of XIAP
expression on the protein level. In contrast, mRNA and protein expression levels of Smac/DIABLO did not significantly change
between early and advanced tumour stages or between low and high tumour grades. Consequently, the mRNA expression ratio
between antiapoptotic XIAP and proapoptotic Smac/DIABLO markedly increased during progression from early (pT1) to advanced
(pT3) tumour stages. Moreover, RCCs confined within the organ capsule (pT1 and pT2) exhibited a significantly lower XIAP to
Smac/DIABLO expression ratio when compared with RCCs infiltrating beyond the kidney (pT3; P¼0.01). Thus, our investigation
demonstrates that the delicate balance between XIAP and Smac/DIABLO expression is gradually disturbed during progression of
RCCs, resulting in a relative increase of antiapoptotic XIAP over proapoptotic Smac/DIABLO, thereby probably contributing to the
marked apoptosis resistance of RCC.
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Resistance to apoptosis plays a critical role during tumorigenesis
and tumour progression, facilitating the accumulation of trans-
forming mutations, promoting evasion of tumour cells from
immunosurveillance and contributing to resistance against anti-
cancer drugs (Gerharz et al, 1999; Reed, 1999; Ramp et al, 2000,
2003a,b; Igney and Krammer, 2002). The molecular pathways of
apoptotic cell death are controlled by genes that either promote or
inhibit the activation of the caspase cascade and, consequently, an
imbalance between proapoptotic and antiapoptotic regulators may
significantly contribute to apoptosis resistance.
Recently, the activity of caspases has been shown to be inhibited
by members of the inhibitor of apoptosis protein (IAP) family
(Salvesen and Duckett, 2002). Up to now, eight human IAP
proteins have been identified: X-linked inhibitor of apoptosis
(XIAP), survivin, c-IAP1, c-IAP2, NAIP, BRUCE, ILP-2 and ML-
IAP (Livin) (Mahotka et al, 1999, 2002a,b; Reed, 1999; Salvesen
and Duckett, 2002). X-linked inhibitor of apoptosis has been
shown to be the most potent caspase-inhibitory IAP family
member that is able to inhibit caspase-3, -7 and -9 (Deveraux
et al, 1999; Huang et al, 2001; Srinivasula et al, 2001). Moreover,
XIAP exhibits E3 ligase activity and is able to ubiquitinate caspase-
3 for degradation by the proteasome (Suzuki et al, 2001). X-linked
inhibitor of apoptosis, therefore, acts as a potent suicide
inactivator, effectively inhibiting apoptosis induced by a variety
of extracellular stimuli, including anticancer drugs and ionising
radiation (Li et al, 2000; Asselin et al, 2001; Holcik et al, 2001;
Matsumiya et al, 2001).
Only recently, three inhibitors of XIAP have been identified,
namely Second Mitochondria-derived Activator of Caspases/Direct
IAP-Binding Protein with Low PI (Smac/DIABLO), Omi/HtrA2
(Hedge et al, 2002; Verhagen et al, 2002; Martins et al, 2003;
Srinivasula et al, 2003) and XIAP-Associated Factor 1 (XAF1) (Fong
et al, 2000; Liston et al, 2001; Verhagen and Vaux, 2002). The
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ymechanism by which XAF1 antagonises the effects of XIAP is not
very well known, but might affect the redistribution of XIAP from the
cytoplasm to the nucleus (Liston et al, 2001). Omi/HtrA2 and Smac/
DIABLO are localised within the mitochondria and are released into
the cytosol upon apoptotic stimuli. Cytosolic Omi/HtrA2 results in
displacement of XIAP from caspases and loss of their suppressive
effect on caspase activity (Hedge et al, 2002; Verhagen et al, 2002;
Martins et al, 2003). Moreover, Omi/HtrA2 was shown to be able to
degrade XIAP protein (Martins et al, 2003; Srinivasula et al, 2003).
Cytosolic and proteolytically processed Smac/DIABLO can also
disrupt the interaction between XIAP and caspases, thereby relieving
the inhibition of caspase-3, -7 and -9 by XIAP (Srinivasula et al, 2001;
van Loo et al, 2002; Verhagen and Vaux, 2002). Since overexpression
of Smac/DIABLO was able to sensitise tumour cells against
anticancer drug- and TRAIL-induced apoptosis (Zhang et al, 2001;
Guo et al, 2002; Ng et al, 2002; Mc Neish et al, 2003), Smac/DIABLO
is thought to be a major antagonist of XIAP.
Importantly, inhibition of apoptosis by IAPs also seems to
promote tumour progression in vivo, suggesting that IAPs might
be used as novel prognostic factors. Thus, AML patients with low
XIAP levels exhibited a significantly longer survival time (Tamm
et al, 2000). Conflicting observations, however, have been reported
between XIAP expression and tumour stage or patient’s survival in
carcinomas of the cervix as well as non-small-cell lung carcinomas
of early or advanced stages (Ferreira et al, 2001a,b; Liu et al, 2001;
Hofmann et al, 2002). Preliminary investigations demonstrated
expression of Smac/DIABLO in 62% of various carcinoma types
(Yoo et al, 2003), but the relation between Smac/DIABLO
expression and tumour staging, grading or survival has not been
analysed yet. Moreover, since XIAP and Smac/DIABLO are major
opponents, it is reasonable to assume that the expression of both –
rather than the expression of a single regulator – may be relevant
for regulating apoptosis susceptibility.
The aim of the present investigation, therefore, was to explore
the relevance of XIAP and Smac/DIABLO expression for tumour
progression in a large cohort of renal cell carcinomas (RCCs) of all
major histological types.
MATERIAL AND METHODS
Patients and specimens
Tumour tissue samples of 66 consecutive RCCs of different
histological types, grades and stages (Table 1) were obtained from
patients who had undergone nephrectomy. The tumour specimens
were immediately flash frozen in liquid nitrogen and stored at
 801C until RNA extraction. Tumour typing, grading and staging
were performed according to the principles outlined by the WHO
(Mostofi and Davis, 1998), Sto ¨rkel et al (1989) and the UICC
(Wittekind and Wagner, 1997). The proportion of the different
RCC types in our study reflects the frequency of each tumour type
in a large RCC series (Mostofi and Davis, 1998).
RNA extraction
Total RNA was isolated by the guanidium thiocyanate extraction
method as described by Chomczynski and Sacchi (1987). After-
wards, the total RNA was purified using the RNeasy minikit with
DNAse treatment according to the manufacturer’s instructions
(Qiagen, Hilden, Germany) to exclude DNA contamination. The
integrity of all tested total RNA samples was verified by intact 18S/
28S rRNA bands in agarose gel electrophoresis.
Reverse transcription
For cDNA synthesis, 1mg of total RNA was reversed transcribed in
a final volume of 20ml containing 15mM of each dNTP (Roche,
Germany), 10U of recombinant RNasin RNase inhibitor (Promega,
Heidelberg, Germany) and 2.5U of AMV reverse transcriptase
(Promega, Heidelberg, Germany) with the corresponding 1  RT
buffer. The following sets of primers were used: an XIAP-specific
oligonucleotide primer (10pmol; 50-TTC CTC GGG TAT ATG GTG
TCT GAT-30) or a Smac/DIABLO-specific primer (10pmol; 50-TTC
AAT CAA CGC ATA TGT GGT CTG-30) that specifically hybridise
at the 30 regions of XIAP and Smac/DIABLO, respectively. The
sequence-specific antisense GAPDH primer was: 50-TGT CAT CAT
ATT TGG CAG GTT T-30 (10pmol). Reverse transcriptions (RTs)
of both of XIAP and GAPDH as well as both of Smac/DIABLO and
GAPDH were performed in the same reactions to avoid variations
in the efficiency of cDNA synthesis. The RT reaction mixtures were
incubated at 551C for 1h.
Quantitative real-time detection PCR
Amplification and quantification of XIAP, Smac/DIABLO and
GAPDH were carried out in the LightCycler (Roche Diagnostics,
Mannheim, Germany) by using a total volume of 20ml, including
2ml1 0  SYBR Green I Fast Start Reaction Mix (Roche Diagnos-
tics, Mannheim, Germany), 3mM MgCl2, 25pmol of each upstream
and downstream XIAP-specific oligonucleotide primers (forward
primer: 50-CCG TGC GGT GCT TTA GTT GT-30; reverse primer: 50-
TTC CTC GGG TAT ATG GTG TCT GAT-30) (GeneBank accession
number U45880), Smac/DIABLO-specific oligonucleotide primers
(forward primer: 50-TGT GAC GAT TGG CTT TGG AGT AAC-30;
reverse primer: 50-TTC AAT CAA CGC ATA TGT GGT CTG-30)
and GAPDH-specific oligonucleotide primers (forward primer: 50-
TTG GTA TCG TGG AAG GAC TCA-30; reverse primer: 50-TGT
CAT CAT ATT TGG CAG GTT T-30), 2ml of first-strand cDNA
template from RT (or water as negative control). Real-time PCR
was carried out in glass capillaries with an initial denaturation step
of 10min at 951C, followed by 50 cycles of 0s at 951C, annealing for
10s at 611C and elongation for 10s at 721C. Melting curve was
directly drawn after amplification.
PCR products were additionally checked by electrophoresis on
3% agarose gels containing ethidium bromide and visualised under
UV transillumination. PCR products were confirmed by DNA
sequencing. Briefly, products were excised from agarose gels and
isolated by QIAquick gel extraction kit (Qiagen, Hilden, Germany).
The purified PCR products were sequenced using the ABI-Prism
BigDye Terminator Cycle Sequencing kit (ABI, Weiterstadt,
Germany) with the respective forward and reverse primers used
in the real-time PCR according to the manufacturer’s protocol.
Sequence analysis was carried out using an ABI-Prism 310.
Quantification of XIAP and Smac/DIABLO by an external
standard
A cDNA fragment of the housekeeping gene GAPDH was cloned.
Plasmids (pGEM-T-easy; Promega, Heidelberg, Germany) were
Table 1 Pathological staging, grading and typing of renal call carcinomas
Staging Grading Typing
XIAP (n¼59) pT1 25 G1 2 Clear cell 46
pT2 20 G2 44 Papillary 11
pT3 14 G3 13 Chromophob 2
Smac/DIABLO (n¼66) pT1 22 G1 1 Clear cell 56
pT2 21 G2 52 Papillary 9
pT3 23 G3 13 Chromophob 1
XIAP/Smac (n¼46) pT1 16 G1 1 Clear cell 37
pT2 17 G2 34 Papillary 8
pT3 13 G3 11 Chromophob 1
Expression of XIAP and Smac/DIABLO in RCCs
Y Yan et al
1350
British Journal of Cancer (2004) 91(7), 1349–1357 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yisolated, linearised by SacI restriction and cleaned. Plasmid
concentration was measured and the number of GAPDH copies
was calculated. Serial dilutions of the linearised GAPDH plasmid
from 6 10
8–3 10
6 copies were prepared. For relative quantifi-
cation of XIAP, Smac/DIABLO and GAPDH copy numbers, a
standard curve was created by plotting the crossing point (CP)
values against the number of copies. Every dilution was run at least
in duplicate. The number of gene copies was calculated by the
LightCycler Software (Version 3.5) according to the second
derivative maximum method.
Western blot analysis
Protein extracts from 12 arbitrarily selected pT1 and pT3 RCCs
were isolated by disrupting flash frozen tissue samples in
lysis buffer (100mM NaCl, 10mM Tris–HCl, pH 7.6, 1mM EDTA,
pH 8.0, 1% NP40 and protease inhibitors). Protein aliquots
(up to 50mg) were electrophoresed in 12% SDS–polyacrylamide
gels at 70mA for 4h. Blotting to Opitran BA-S85 nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany) was
performed for up to 2h at 650mA in a tank of transfer buffer
(25mM Tris–HCl, 192mM glycine, 20% methanol; pH 8.3), using
the Hoefer TE series Transphor Electrophoresis Unit (Hoefer
Scientific Instruments, San Francisco, USA). To verify transfer
efficiency, nitrocellulose membranes were stained with 0.2%
Ponceau S. The membranes were blocked for 2h at 41Ci n
blocking buffer (100mM Tris–HCl, pH 7.5, 150mM NaCl, 0.2%
Tween 20) plus 3% non-fat dry milk and 1% BSA, incubated
overnight at 41C with the polyclonal rabbit anti-human XIAP
antibody (No. 2042, Cell Signaling Technology, England) by
dilution of 1:500, and incubated after washing with the horse-
radish peroxidase-linked donkey anti-rabbit antibody for 1h at
room temperature by 1:2000 dilution. After washing, the protein
was visualised by incubation with Lumi-Light substrate (Roche,
Mannheim, Germany). Equal amounts of the loaded protein
samples were confirmed by b-actin detection with the mouse
monoclonal anti-human b-actin antibody (clone AC-15; Sigma-
Aldrich, Deisenhofen, Germany).
Enzyme-linked immunosorbent assay (ELISA)
For quantification of Smac/DIABLO protein expression in
RCCs, quantitative sandwich ELISA was carried out using the
DuoSet
s IC assay kit (R&D Systems, Wiesbaden, Germany) as
described by the manufacturer’s manual. Briefly, proteins
were isolated from 24 arbitrarily selected clear cell RCCs (pT1:
n¼8, pT2: n¼8, pT3: n¼8) and diluted to a concentration of
400mgml
 1. A standard curve was generated by using two-fold
serial dilutions and a high standard of 5000pgml
 1. A 96-well
microtitre plate was coated overnight at room temperature by
capture antibody and, after washing with washing buffer
(0.05% Tween 20 in PBS, pH 7.3), blocked with blocking buffer
(1% BSA, 5% sucrose in PBS, pH 7.3, with 0.05% NaN3) for 2h,
followed by washing. Samples or standards of 100ml were added in
duplicate and incubated for 2h. After washing, 100mlo f
biotinylated rabbit anti-human Smac/DIABLO antibody (R&D
Systems, Wiesbaden, Germany; concentration 150ngml
 1) was
added to each well and incubated for 2h. After washing again,
100ml of streptavidin conjugated to horseradish peroxidase
(1:200 dilution) was added and incubated for 20min, followed
by washing. In all, 100ml of substrate solution (1:1 mixture of
H2O2 and tetramethylbenzidine) was added and incubated for
20min, and then stopped by 2 N H2SO4. Optical density was
determined immediately at 450 and 570nm in a spectrophotometer
and the values at 570nm were subtracted from the values at
450nm. The absorbances after subtraction were directly used for
statistical analysis.
Statistical analysis
GAPDH copy numbers (external standard) were used to normalise
the copy numbers of XIAP and Smac/DIABLO, calculating ratios of
relative mRNA levels of XIAP, Smac/DIABLO and XIAP to Smac/
DIABLO. Statistical analysis was performed using the Mann–
Whitney and Wilcoxon tests with the statistical software package
SPSS 11.0 (SPSS, Chicago, USA). A P-value of less than 0.05 was
considered to indicate the statistical significance.
RESULTS
Quantification of XIAP and Smac/DIABLO expression
X-linked inhibitor of apoptosis, Smac/DIABLO and the house-
keeping gene GAPDH could be detected at cycles 19–42, 24–38
and 17–26, respectively (Figure 1A–C). The specificity of the
amplification products was confirmed by agarose gel electrophor-
esis, which revealed distinct bands for all PCR products (Figure 1d)
and by DNA sequencing (data not shown). Cloning of a GAPDH
cDNA fragment permitted the generation of a standard curve by
serial dilution (Figure 2). The standard curve with a correlation
coefficient of 0.99 was used for a relative quantification of the copy
numbers obtained from XIAP, Smac/DIABLO and GAPDH in each
tumour sample. GAPDH copy numbers were used as an external
standard to normalise the copy numbers of XIAP and Smac/
DIABLO, calculating the relative mRNA levels (i.e. GAPDH-
normalised mRNA expression level).
Tumour stage- and grade-dependent increase of XIAP
expression
mRNA expression of XIAP was found in all RCCs (n¼59),
irrespective of their tumour stages, grades or histological types.
As can be seen in Figure 3A and B, the relative mRNA
expression levels of XIAP significantly increased from early (pT1)
to advanced tumour stages (pT3). Importantly, RCCs infiltrating
beyond the kidney (pT3) exhibited significantly higher relative
XIAP mRNA expression levels when compared with tumours
confined to the organ (pT1 and pT2; P¼0.002; Figure 3A and B).
Quite similarly, XIAP mRNA expression significantly increased
with tumour dedifferentiation (Figure 3C). Thus, the relative
expression level of XIAP was significantly higher in poorly
differentiated RCCs (G3) than in well and moderately differ-
entiated tumours (G1 and G2; P¼0.04).
Moreover, RCCs of the clear cell type, which were reported to
exhibit a poorer prognosis than papillary RCCs (Cheville et al,
2003) showed higher XIAP expression levels when compared with
XIAP levels in papillary RCCs (Figure 3D), although the difference
was of borderline significance only (P¼0.05).
Since XIAP expression is known to be regulated transcription-
ally and post-transcriptionally (Tamm et al, 2000; Holcik et al,
2001; Hofmann et al, 2002), we also performed Western blot
analysis in 12 arbitrarily selected RCC tumour samples of early and
advanced tumour stages (pT1: n¼6, pT3: n¼6). These investiga-
tions revealed a distinct XIAP signal of the expected size (53kDa)
in all RCCs (Figure 4). Remarkably, a stage-dependent increase of
XIAP expression became evident also on the protein level
(Figure 4), thereby further confirming our results on increased
XIAP mRNA expression in advanced tumour stages.
Our results, therefore, demonstrate an increase in antiapoptotic
XIAP mRNA and protein expression during tumour progression.
Constant expression of Smac/DIABLO irrespective of
tumour stage and grade
Since Smac/DIABLO is known to be a major antagonist of XIAP
(van Loo et al, 2002; Verhagen and Vaux 2002), we also analysed
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in RCCs.
mRNA expression of Smac/DIABLO was also found in all
RCCs (n¼66), irrespective of their staging, grading or histological
typing.
Importantly, as shown in Figure 5A–D, the relative mRNA
expression levels of proapoptotic Smac/DIABLO did not signifi-
cantly change between early and advanced tumour stages (Figure
5A and B) or between low and high tumour grades (Figure 5C).
Similar Smac/DIABLO mRNA levels were observed in RCCs of the
clear cell and papillary types (Figure 5D).
To analyse whether Smac/DIABLO expression remains constant
also at the protein level, we investigated the corresponding protein
expression in 24 arbitrarily selected RCCs of different tumour
stages by ELISA. As can be seen in Figure 6, Smac/DIABLO protein
levels showed no significant differences between different tumour
stages.
Our results, therefore, demonstrate that expression of Smac/
DIABLO mRNA and protein remains constant during RCC
progression.
Increased expression ratio of XIAP to Smac/DIABLO
during tumour progression
Recent observations demonstrated an inverse expression pattern
of XIAP and Smac/DIABLO after TRAIL-, UV-B-, and drug-
induced apoptosis (Chow et al, 2003; Griffin et al, 2003; Takasawa
and Tanuma, 2003), suggesting that the relative ratio between
XIAP and Smac/DIABLO is crucial to determine apoptosis
susceptibility.
We, therefore, calculated the ratio between antiapoptotic XIAP
and proapoptotic Smac/DIABLO mRNA expression levels in
different tumour stages. As demonstrated in Figure 7, the mRNA
expression ratio between XIAP and Smac/DIABLO markedly
increased during progression from early (pT1) to advanced
(pT3) tumour stages. Importantly, RCCs confined to the organ
capsule (pT1 and pT2) exhibited a significantly lower expression
ratio between XIAP and Smac/DIABLO when compared with
advanced RCCs infiltrating beyond the kidney (pT3; P¼0.01).
Thus, our investigation demonstrates that the delicate balance
between XIAP and Smac/DIABLO expression is gradually dis-
turbed during progression of RCCs, resulting in a relative increase
of antiapoptotic XIAP over proapoptotic Smac/DIABLO.
DISCUSSION
The present investigation demonstrates for the first time a stage-
and grade-dependent increase of antiapoptotic XIAP expression in
human RCCs. In contrast, the mRNA and protein levels of its
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Figure 1 Analysis of XIAP and Smac/DIABLO mRNA expression in renal cell carcinomas by real-time detection PCR and agarose gel electrophoresis.
(A–C) SYBR green I-mediated fluorescence (y-axis) of the respective amplification products was measured once per cycle (x-axis). X-linked inhibitor of
apoptosis (A), Smac/DIABLO (B) and GAPDH (C) were detectable at cycles 19–42, 24–38 and 17–26, respectively. Comparative analysis of GAPDH
transcripts was used as reference. (D) The specificity of the corresponding XIAP, Smac/DIABLO and GAPDH amplification products from RCCs of different
stages were demonstrated by agarose gel electrophoresis, showing specific products at the calculated sizes at the end point of LightCycler PCR.
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Figure 2 GAPDH standard curve. (A) Calibration of GAPDH standard
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6 copies in duplicate visualised on agarose gel. (B)
LightCycler-based standard curve report for serially diluted GAPDH
plasmid amplification. The cycle number was plotted against the log of
concentration by the second derivative maximum method. A correlation
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Expression of XIAP and Smac/DIABLO in RCCs
Y Yan et al
1352
British Journal of Cancer (2004) 91(7), 1349–1357 & 2004 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yantagonist Smac/DIABLO remained constant, resulting in an
increased expression ratio between XIAP and Smac/DIABLO
during tumour progression.
Suppression of apoptosis promotes tumour progression, im-
mune evasion of neoplastic cells as well as resistance to
chemotherapy and irradation (Gerharz et al, 1999; Mahotka et al,
1999; Reed, 1999; Ramp et al, 2000, 2003a,b; Igney and Krammer
2002; Mahotka et al, 2002a,b). Several genes critical in the
regulation of apoptosis have been identified, including XIAP – a
member of the IAP family. X-linked inhibitor of apoptosis is
thought to act as a key determinant of apoptosis resistance by
effectively inhibiting the activation of caspase-3, -7 and -9
(Deveraux et al, 1999; Holcik et al, 2001; Srinivasula et al, 2001;
Suzuki et al, 2001). Thus, high expression of XIAP has been
reported in many malignant tumour types, such as carcinomas of
the breast, ovaries, lung, pancreas, cervix and prostate (Ferreira
et al, 2001a,b; Liu et al, 2001; Gerhard et al, 2002; Hofmann et al,
2002; Mc Eleny et al, 2002; Parton et al, 2002; Sui et al, 2002) as
well as leukaemias (Tamm et al, 2000). Moreover, upregulation of
XIAP expression has been found to result in apoptosis resistance
after exposure to anticancer drugs and ionising radiation (Li et al,
2000; Asselin et al, 2001; Holcik et al, 2001; Matsumiya et al, 2001),
whereas downregulation of XIAP by antisense vectors increased
the apoptosis sensitivity of carcinoma cell lines (Sasaki et al, 2000;
Holcik et al, 2001).
In our study, we found XIAP expression in all RCCs of all major
histological types. This observation further confirmed the ubiquity
of XIAP expression in human cancers, as reported earlier for other
tumour types (Tamm et al, 2000). Importantly, we could
demonstrate for the first time in RCCs that XIAP mRNA
expression levels significantly increased from early (pT1) to
advanced tumour stages (pT3) and – quite similarly – also with
tumour dedifferentiation. Moreover, RCCs of the clear cell type,
which were reported to exhibit a poorer prognosis than papillary
RCCs (Cheville et al, 2003), showed a tendency for higher XIAP
expression. Since XIAP expression is known to be also post-
transcriptionally regulated, we additionally performed Western
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Figure 3 Analysis of GAPDH-normalised XIAP mRNA expression in RCCs. (A) Significant increase of antiapoptotic XIAP mRNA expression from early
(pT1) to advanced tumour stages (pT3). (B) Significantly higher XIAP mRNA levels in RCCs infiltrating beyond the kidney (pT3) when compared with RCCs
confined to the organ (pT1þpT2). (C) Significant increase in XIAP levels with dedifferentiation of RCCs. (D) Tendency for higher XIAP expression levels in
clear cell RCCs when compared with the papillary type.
pT1 pT3
MW (kDa)
53
42
XIAP
-Actin
Figure 4 Western blot analysis of XIAP expression in 12 arbitrarily
selected clear-cell RCCs. Higher XIAP protein expression in advanced
RCCs (pT3) when compared with early tumour stage (pT1). Equal
amounts of loaded proteins were confirmed by re-incubation of the filters
with an antibody against b-actin.
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advanced tumour stages and could confirm the tumour stage-
dependent increase of XIAP expression on the protein level.
Similarly, a correlation between XIAP mRNA and protein levels
was previously reported in non-small-cell lung carcinomas
(Hofmann et al, 2002).
Since tumour stage and grade are considered as major
prognostic parameters in RCC (Srigley et al, 1997), our results
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Figure 5 Analysis of GAPDH-normalised Smac/DIABLO mRNA expression in RCCs. (A, B) No significant changes of Smac/DIABLO mRNA expression
from early (pT1) to advanced (pT3) tumour stages and between RCCs infiltrating beyond the kidney (pT3) and confined to the organ (pT1þpT2). (C, D)
No significant differences between low (G1þG2) and high tumour grades (G3) or between clear cell and papillary tumour types.
pT1 pT1+2 pT2 pT3 pT3
Tumour staging Tumour staging
P = 0.44 P = 0.51
P = 0.57
P = 0.98
2.0
2.5
3.0
3.5
S
m
a
c
 
/
D
I
A
B
L
O
 
a
b
s
o
r
b
a
n
c
e
AB
Figure 6 Analysis of Smac/DIABLO protein expression by quantitative ELISA in 24 arbitrarily selected RCCs. (A, B) No significant differences in Smac/
DIABLO protein expression between early (pT1) and advanced (pT3) tumour stages or between RCCs confined to the organ (pT1þpT2) and infiltrating
beyond the kidney (pT3).
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ymight also suggest that RCCs with a strong XIAP expression
exhibit a poorer clinical outcome. The corresponding results were
previously reported in AML, where patients with higher XIAP
levels exhibited a significantly shorter survival time (Tamm et al,
2000). It is reasonable to assume, therefore, that in RCCs – and
probably also in AML – increased expression of antiapoptotic
XIAP contributes to reduced apoptosis susceptibility of tumour
cells, thereby providing an important survival advantage during
tumour progression. Conflicting observations, however, have been
reported between XIAP expression and tumour stage or survival in
other tumour types. In these reports, no correlation between XIAP-
expression levels and tumour stage, grade or survival was observed
in patients with carcinomas of the cervix, non-small-cell lung
carcinomas and advanced nonresectable non-small-cell lung
carcinomas treated by chemotherapy alone (Liu et al, 2001;
Ferreira et al, 2001a; Hofmann et al, 2002), whereas high XIAP-
expression levels were associated with longer survival in patients
with radically resected non-small-cell lung carcinomas (Ferreira
et al, 2001b).
Susceptibility for apoptosis is controlled by a multitude of
anti- and proapoptotic regulators. Whereas antiapoptotic
XIAP has been shown to be a potent caspase inhibitor (Deveraux
et al, 1999; Holcik et al, 2001; Srinivasula et al, 2001; Suzuki et al,
2001), its antagonists Smac/DIABLO and Omi/HtrA2 promote
apoptosis by binding to XIAP, thereby preventing them
from inhibition of caspases (Verhagen et al, 2000, 2002; Martins
et al, 2003). Importantly, overexpression of Smac/DIABLO
sensitises tumour cells against anticancer drug- and TRAIL-
induced apoptosis (Zhang et al, 2001; Guo et al, 2002; Ng et al,
2002; Mc Neish et al, 2003). Only recently, an inverse relation
between XIAP expression and mitochondrial release of Smac/
Diablo has been observed after apoptosis induction in colon
cancer cells, lymphoma cells and keratinocytes (Chow et al, 2003;
Takasawa and Tanuma, 2003; Tillman et al, 2003). Moreover, XIAP
protein was shown to function as an E3 ligase in the ubiquitination
of Smac/DIABLO, thereby promoting its rapid degradation (Mac
Farlane et al, 2002). These observations indicate a tight regulation
of these opponents and might also suggest that the expression ratio
– rather than the expression of a single regulator – effectively
controls susceptibility for apoptosis. Investigations, however,
analysing the expression of XIAP and Smac/DIABLO in relation
to tumour stage, grade and type are lacking up to now. In our
study, the mRNA and protein expression levels of Smac/DIABLO
remained stable during RCC progression and did not significantly
change between early and advanced tumour stages, low and high
tumour grades as well as different types of RCCs. Since XIAP
expression significantly increased during tumour progression, the
expression ratio between XIAP and Smac/DIABLO also markedly
increased during progression from early to advanced RCC stages.
Thus, the delicate balance between XIAP and Smac/DIABLO is
gradually disturbed during progression of RCCs, probably
resulting in an increased inability for Smac/DIABLO to antagonise
the antiapoptotic effects of XIAP. Although investigations con-
cerning the expression of Omi/HtrA2 in relation to tumour stage
and grade are lacking, it is reasonable to assume that the disturbed
balance between XIAP and Smac/DIABLO during progression of
RCCs cannot be adjusted by Omi/HtrA2.
Importantly in this context, TNF- and folic acid-induced
apoptosis in tubular epithelial cells, considered to be the cells
of origin for clear cell and papillary RCC, has recently been
shown to be associated with increased mRNA and protein
expression of Smac/DIABLO (Justo et al, 2003). Carcinogenesis
in tubular epithelial cells, therefore, might be associated with an
inability to upregulate Smac/DIABLO expression, thereby generat-
ing an important selective growth advantage. Moreover, the
inappropriate increase of antiapoptotic XIAP over proapoptotic
Smac/DIABLO during progression of RCCs promotes the acquisi-
tion of apoptosis resistance, which might also contribute to the
clinically known resistance of RCCs to anticancer drugs and
irradation.
In conclusion, our investigation demonstrates for the first
time a stage- and grade-dependent increase of antiapoptotic
XIAP expression in RCCs, whereas the mRNA and protein levels of
its antagonist Smac/DIABLO remained constant. As a conse-
quence, the delicate balance between XIAP and Smac/DIABLO
expression is gradually disturbed during progression of
RCC, probably contributing to the marked apoptosis resistance
of RCCs.
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Figure 7 Ratio of antiapoptotic XIAP to proapoptotic Smac/DIABLO mRNA expression in different tumour stages. (A) Significant increase in the
expression ratio between XIAP and Smac/DIABLO, comparing early (pT1) and advanced (pT3) tumour stages and (B) of RCCs confined to the organ
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